Ekonomi Bölümü Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.11779/1936
Browse
8 results
Search Results
Article Citation - WoS: 2Citation - Scopus: 4Heterogeneous Impact of Innovation on Economic Development: Evidence from EU Regions(Elsevier Sci Ltd, 2026-03-01) Pinar, Mehmet; Karahasan, Burhan CanThis paper investigates the heterogeneous impact of innovation on economic development across European Union (EU) regions, with a focus on regional competitiveness driven by innovation-based capabilities. While innovation is a key driver of economic growth, its effects are not uniformly distributed. Using the Multiscale Geographically Weighted Regression models, the study examines how different dimensions of innovation (technological readiness, business sophistication, and overall innovation capacity) affect regional GDP per capita. The results show that regions with higher innovation-based competitiveness generally achieve higher income levels. However, the impact of innovation is spatially uneven. While core EU regions (particularly, in Northern and Western Europe) benefit more strongly from innovation, peripheral regions (in Southern and Eastern Europe) often experience weaker and in some cases even negative, effects. These results highlight the importance of accounting for spatial variation when designing innovation and cohesion policies. The paper calls for tailored, place-based strategies to address regional disparities in innovation-driven development and suggests that current EU policies should be adjusted to better support lagging regions.Article Citation - WoS: 6Citation - Scopus: 8Arbitrageur Behavior in Sentiment-Driven Asset-Pricing(World Scientific Publishing, 2021-09-01) Kılıç, Erdem; Oğuzhan, Göksel; Goksel, OguzhanThis study aims to model arbitrageur behavior in a sentiment-driven capital asset-pricing model under the premise of reflecting a more detailed decomposition of investor types in the equity markets. We explore the behavior and the impact of arbitrageur behavior, particularly, on pricing and on key financial ratios. We observe that the prevalence of the arbitrageur counteracts the effects of unsophisticated investors, resulting in a lower volatility of the price–dividend ratio, lower predictive power of changes in consumption for future price changes and lower equity premium. Thus, the results of our research allow us to conjecture that the extrapolation bias in the prices is lowered.Conference Object A Comparative Analysis of the Health Care Utilization and Costs of Patients Diagnosed With and Without Liver Cancer in the Us Medicare Population(2017) Ogbomo, A.; Lin, Y.; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object The Role of Stakeholder Engagement in E-Health and the Use of Big Data To Predict Health Outcomes(2017) Cinaroğlu, S.; Başer, Onur...Conference Object Socio-Economic Status and Self-Rated Health: Are They Good Predictors of Income? an Analysis of Survey Panel Data From Turkey(Elsevier Science Inc, 2016) Çınaroğlu, Songül; Başer, Onur...Conference Object Pmh1 - Healthcare Utilization and Costs of Serotonin Syndrome With Concomitant Use of Serotonergic Agents(Elsevier Science Inc, 2015-05-01) Wang, Z.; Xie, L.; Nguyen, C; Alley, S.; Başer, OnurOBJECTIVES: Serotonin syndrome (SS) is an adverse drug reaction that may occurin patients receiving monotherapy or combinations of serotonergic agents (SAs).This study examined healthcare utilization and costs of SS in two different populations. METHODS: Adult (age ?18 years) patients prescribed SAs were identifiedusing the Veterans Health Administration (VHA) dataset (01OCT2008-30SEPT2012) andthe IMS PharMetrics Plus dataset (01JAN2010-31DEC2013). Patients with continuoushealth plan enrollment 12 months pre-index date, defined as the first SA prescription claim date, were included and observed until death, disenrollment or the end ofthe study period. Patients were assigned to cohorts based on drug exposure: singlemonoamine oxidase inhibitor (MAOI) drug, MAOI drugs in combination with otherSAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, and ?5 SAs). Outcomesof interest were annual incidences of SS event (ICD-9-CM: 333.99) and associatedhealth care utilization and costs.Conference Object Examining Health Care Utilization and Costs Among Atherosclerosis Patients in the Us Veteran Health Administration Population(2017) Zhang, Q.; Kariburyo, M. T.; Xu, J.; Başer, Onur...Conference Object Psy14 - Evaluating Trends in Chronic Pain Prevalence in the United States Veterans Health Administration Population(Elsevier Science Inc, 2015-05-01) Li, L.; Shrestha, S.; Başer, Onur; Yuce, H; Wang, LOBJECTIVES: The current study examined chronic pain prevalence in the U.S. Veterans Health Administration (VHA) population. METHODS: The study sample was based on the VHA Medical SAS Datasets from fiscal year 2008 through 2012. All patients diagnosed with chronic pain throughout the study period were identified using International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes 338.2 and 338.4. The variation in the prevalence of chronic pain was assessed and categorized according to the pain scale. Pain score was determined using a scale ranging from 0 to 10 as reported by patients using the following categories: 1 to 4: mild, 5 to 6: moderate and ?7: severe pain. To identify prior prevalence cases, we restricted continuous enrollment throughout that fiscal year and at least 2 years prior
